Chester County News and Community Website
WASHINGTON, D.C. — Federal regulators are proposing new limits on the compounding of several widely used diabetes and weight-loss drugs, a move that could reduce access to lower-cost alternatives when …
FDA Moves to Restrict Compounded Weight-Loss Drugs Read More
PHILADELPHIA, PA — The City of Philadelphia has launched a sweeping lawsuit against some of the nation’s largest pharmacy benefit managers and insulin manufacturers, accusing them of orchestrating a pricing …
Philadelphia Sues PBMs, Drugmakers Over Insulin Prices That Skyrocketed Read More
HARRISBURG, PA — Attorney General Dave Sunday has issued a warning to Pennsylvanians about the risks of counterfeit GLP-1 receptor agonist drugs, which are widely used for managing diabetes and …
Counterfeit GLP-1 Drugs Threaten Lives: Urgent Warning for Pennsylvanians Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first rapid-acting insulin biosimilar to Novolog (insulin aspart). This new treatment option, aimed at …
FDA Approves Groundbreaking Rapid-Acting Insulin Biosimilar Merilog, Offering New Hope for Millions Battling Diabetes Read More WASHINGTON, D.C. — The fight against type 2 diabetes just reached a groundbreaking milestone. Last week, the U.S. Food and Drug Administration (FDA) approved the first generic version of liraglutide injection, …
FDA Approves First Generic Liraglutide Injection, Ushering in a New Era for Type 2 Diabetes Treatment Read More
LANGHORNE, PA — Amplity Health shared valuable findings from its latest study on GLP-1 receptor agonist (GLP-1 RA) usage patterns during the ISPOR Europe 2024 conference. The research, based on …
Amplity Health Reveals Key Insights on GLP-1 Receptor Agonist Usage at ISPOR Europe 2024 Read More